The stock price of Tscan Therapeutics Inc (NASDAQ: TCRX) has dropped by -9.69 compared to previous close of 1.60. Despite this, the company has seen a fall of -9.12% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-07 that Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barring positive feedback from regulatory authorities, the company hopes to develop TSC-101 for AML, MDS, ALL patients who undergo HSCT in a pivotal study in the 2nd half of 2025. The company is developing multiplex TCR-Ts for treatment of patients with solid tumors, with phase 1 PLEXI-T trial data anticipated in the second half of 2025.
Is It Worth Investing in Tscan Therapeutics Inc (NASDAQ: TCRX) Right Now?
The stock has a 36-month beta value of 0.98. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TCRX is 43.27M, and at present, short sellers hold a 5.14% of that float. On March 26, 2025, the average trading volume of TCRX was 438.61K shares.
TCRX’s Market Performance
TCRX stock saw a decrease of -9.12% in the past week, with a monthly decline of -32.16% and a quarterly a decrease of -50.68%. The volatility ratio for the week is 13.50%, and the volatility levels for the last 30 days are 11.12% for Tscan Therapeutics Inc (TCRX). The simple moving average for the last 20 days is -19.83% for TCRX’s stock, with a simple moving average of -68.59% for the last 200 days.
Analysts’ Opinion of TCRX
Many brokerage firms have already submitted their reports for TCRX stocks, with BTIG Research repeating the rating for TCRX by listing it as a “Buy.” The predicted price for TCRX in the upcoming period, according to BTIG Research is $12 based on the research report published on May 16, 2024 of the previous year 2024.
Needham, on the other hand, stated in their research note that they expect to see TCRX reach a price target of $11. The rating they have provided for TCRX stocks is “Buy” according to the report published on May 13th, 2024.
Wedbush gave a rating of “Outperform” to TCRX, setting the target price at $8 in the report published on June 22nd of the previous year.
TCRX Trading at -32.08% from the 50-Day Moving Average
After a stumble in the market that brought TCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.09% of loss for the given period.
Volatility was left at 11.12%, however, over the last 30 days, the volatility rate increased by 13.50%, as shares sank -29.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.83% lower at present.
During the last 5 trading sessions, TCRX fell by -9.12%, which changed the moving average for the period of 200-days by -83.67% in comparison to the 20-day moving average, which settled at $1.8027. In addition, Tscan Therapeutics Inc saw -52.47% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TCRX starting from Lynx1 Capital Management LP, who purchase 100,000 shares at the price of $2.90 back on Dec 13 ’24. After this action, Lynx1 Capital Management LP now owns 5,357,347 shares of Tscan Therapeutics Inc, valued at $290,140 using the latest closing price.
Lynx1 Capital Management LP, the 10% Owner of Tscan Therapeutics Inc, purchase 31,800 shares at $3.01 during a trade that took place back on Dec 12 ’24, which means that Lynx1 Capital Management LP is holding 5,257,347 shares at $95,629 based on the most recent closing price.
Stock Fundamentals for TCRX
Current profitability levels for the company are sitting at:
- -47.88 for the present operating margin
- 0.16 for the gross margin
The net margin for Tscan Therapeutics Inc stands at -45.28. The total capital return value is set at -0.4. Equity return is now at value -65.08, with -39.64 for asset returns.
Based on Tscan Therapeutics Inc (TCRX), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at -1.14. The debt to equity ratio resting at 0.4. The interest coverage ratio of the stock is -36.91.
Currently, EBITDA for the company is -119.74 million with net debt to EBITDA at 0.68. When we switch over and look at the enterprise to sales, we see a ratio of 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.14.
Conclusion
To sum up, Tscan Therapeutics Inc (TCRX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
